New Investor as of July 2013, but small biotech Investor.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No. I believe those deaths occurred, according to the interview, in the phase 2/3 moderate trial... which is understandable, especially if they happened on placebo side, which totally makes sense. We just don’t have certainty that it was only on the placebo side because that part of the data is not known/unblinded.
What surprises me now is the share price. After watching the interview and hearing Nader talk about using Leronlimab as an HIV cure just as I had predicted... if that happens, $500 sp could become easily the floor.
This was a great interview from addressing the ‘report’ to clinical progress.
The icing on the cake for me was when Nader publicly offered the two modes of reporting these type of events. Nobody willingly provides that info if they have something to hide or have done something illegal. Lol.
The revenge was sweet in that interview, regardless of today’s share price.
I can’t get it to fully open before the website “crashes”.
Well, the link to the report no longer works if that helps.
We went through this before with the ever so impressive Culper report, and guess what?... Cytodyn and Leronlimab kept moving forward. Nothing has changed from 2 weeks ago except an increase in negative insinuation.
The fundamentals remain. Leronlimab for the win.
It was also right before expected Covid data. So of course they can claim “no data”... it hasn’t been released yet and it’s coming! It’s a technical half-truth. But completely disingenuous.
LMAO! Brilliant!
Additionally, the mechanism of action provides patients receiving Leronlimab benefits that would not be found with any other medication. To narrow the treatment down to just the IL6 may provide benefits that helps to recover people from Covid, but the morbidity Of Covid also comes from the inflammatory processes that are outside the IL6 pathway.
Glad to have another drug on board, but Leronlimab is first in class.
Stay tuned till ten years from now people! LMAO!
Somehow, when it’s in red, it means more. Lol. But in all seriousness, it’s a statement of a non-binding agreement essentially. No red flags here... just red font.
It will be interesting to see the data and where approval timeline lands.
Crazy days for sure! Leronlimab for the win!
Ha ha. Awesome!
Nader knows that the US is potentially about to get caught with its pants down in a full on pandemic if Mexico approves Leronlimab first and starts turning the tide of Covid around. Pressure on the fda indeed.
Here’s the kicker though. The average savings is $12,000 per patient according to the open letter from Gilead CEO. ( http://investors.gilead.com/news-releases/news-release-details/open-letter-daniel-oday-chairman-ceo-gilead-sciences ) But here’s something to chew on...
Remdesivir has exclusionary criteria, and the drug is supposedly helping patients doscharge an average of four days earlier, but it doesn’t help with mortality, and likely doesn’t help much in terms of cost when patient upgrades to ICU, intubation, etc.
They are pricing their drug on the average savings of discharging early... the same benchmark that got remdesivir approved. That’s it. Nothing regarding any hard core data surrounding measurable clinical improvement, or the extra cost of upgrading a patient’s care because that’s not how remdesivir works generally speaking.
In other words,Remdesivir only makes those people discharge a little quicker who were already going to survive in the first place. Remdesivir’s zero impact on mortality proves that.
NOW price Leronlimab.... clinically proven to measurably abate the cytokine storm and demonstrated to bring back the sickest of the sick off of ventilators and the brink of death.
In my opinion, Gilead has no choice but to price it the way they did. Anything else would have eaten them up alive PR wise once Leronlimab is on the market. To make it LOOK as though it was a humanitarian decision was an easy way to fold their cards.
All in my opinion!
Right on!
And I’m sure that reports like these are written, in the professional manner that they are, with your and my Investment health and security in mind. Coronacrapper? What are we?... five years old? There’s only one reason why someone would go to such lengths to piecemeal a hit piece this outlandish. It’s because they don’t have positive clinical data to report to ANY legitimate reporting source, or even get an honorable mention in any news source.
Covid data is coming. Tic Toc, Tic Toc. And the Current share price and massively historic daily share trades are proving that it’s NOT snake oil.
See you in December!
It’s so illegal, it’s risen to $7.00!!!! LMAO! Great post, Scooter!
Funny your name is 3x charm. This is the third OTC biotech I’ve invested in and it really is the charm.
Even with a share increase, the truth is that Covid isn’t going to go away anytime soon. We are seeing a resurgence, and cases that move in to moderate/severe cytokine storm still needs to be mitigated. Unfortunately it works to Leronlimab’s advantage from a market perspective, even though it means more people are getting sick. All we need is positive Covid data, and boom. This is just the tip of the iceberg... why? Because Leronlimab has the ability to address a patient’s co-morbidities that may benefit the patient that may be unrelated to their Covid, but contribute to their status level in the hospital.
This drug is going to make Humira look like a tic-tac.
See you in December!
Ha ha. Nope. Lol!
See you in December! Lol.
Just got an E*TRADE alert for special meeting to vote to increase to 800,000,000 shares. Anyone else got it?
I’m wondering if it has to do with residual RANTES levels. It will be interesting to see the full data from phase II mild/moderate. A patient may receive two doses one week apart and ‘recover’, but I wonder if any residual RANTES is left over still triggering subdued inflammatory processes in the body. Would be nice if Dr. P or someone else clarifies that.
Covid AND cancer?! Gee... if there was only a medication that could potentially treat both! Hmmm....
Yep! Uplisting will be the only reason. Correct! DOJ? Link please?
Of course there will be a trading suspension... when they uplist. LMAO!
When you have deadlines, you strike while the iron is hot. We’re talking about right now. But thanks for looking in the rear view mirror! LMAO!
File for Bankruptcy! LMAO!
They could sell 100,000,000 shares right now for $5 per share and Sail on through. One of MANY possibilities that would secure their future. And that’s not even the BEST possibility!
“Educating” LMAO.
‘Educating’ is finding yourself jumping in after so many who did their due diligence before you. LMAO!
LMAO!
Exactly. To deny the science in such a way is really to work against a remarkable drug getting to market. At the thing is, it could be any one of us that could benefit from this drug in the future. Does anyone really think about that? I’m sure if I came down with Covid six months from now, I’d be asking for Leronlimab immediately. That’s a no-brainer.
The drug is the true catalyst, but NP cannot be discounted in it all. He may have his faults, but it is under his leadership that we got here.
Yeah, that’s because a few of those would plop them in the moderate/severe trial.
Right on, brotha. 1-2 weeks and then go time.
I wonder if they will lump a partnership with an announcement. That would be awesome. Doubt it will happen that quickly, but would be sweet: phase 2 data, phase 2/3 interim data, and partnership.... one can dream.
So you’re just now learning that Cytodyn is a pre-revenue biotech? LMAO!
Yep. The term I have coined is an IDM (Industry Disrupting Molecule). For the exact reasons you point out.
And how much did they now about immune therapy then? The role of monoclonal antibodies? When was Humira approved by the fda? 2002.
Where is it now that NP is CEO? $5 share price, HIV BLA submission, Basket trial for cancer, completed Covid trial for mild/moderate, trial for moderate/severe Covid still finishing, with Nash and MS trials soon to start.
Seems like the science has made some advancement in the last few years. I wonder why?.... LMAO.
Not me. Data showing that natural infection doesn’t incur much of an immunity. What does that say about the threshold for any viable vaccine?
I really believe a robust and trusted vaccine Is going to take a while and not work as long as we would like. But that’s just my opinion. Unless someone can provide a link to proof that vaccine would actually provide some level of sustained protection. I really think there may actually be more hope in neutralizing the virus itself than a vaccine. Time will tell.
How many days of legs up and news does it take for shorts to fall out of bed and sober up, Ohm? Lol.
A little investigation is all that is needed to provide clarity with concerns over CEO pay. And payday will be huge for everyone else.... if kinda isn’t already. Just depends on when you want to take profit at this stage, not IF.
Very pointed Scooter. Interesting times indeed.